Table 3.
Multivariable analysis of clinicopathological features associated with overall survival and recurrence for patients with HPV-associated oropharyngeal SCC undergoing TORS-based therapy
| Clinicopathological feature | Overall survival | Locoregional recurrence | Overall recurrence (locoregional + distant) |
|||
|---|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value | |
| ENE | 1.29 (0.23–7.18) | 0.77 | 1.64 (0.40–6.72) | 0.49 | 2.37 (0.99–5.65) | 0.05 |
| PNI | 3.39 (0.62–18.61) | 0.16 | 1.65 (0.35–7.86) | 0.53 | 2.15 (0.83–5.51) | 0.11 |
| LVI | 0.24 (0.03–2.08) | 0.20 | 1.42 (0.46–4.34) | 0.54 | 1.76 (0.80–3.84) | 0.16 |
| Positive margins | 1.81 (0.35–9.41) | 0.48 | 4.24 (1.26–14.26) | 0.02 | 3.48 (1.47–8.23) | 0.004 |
| Adjuvant therapy | 1.17 (0.25–5.60) | 0.84 | 0.12 (0.03–0.50) | 0.004 | 0.33 (0.13–0.84) | 0.02 |